Forget the Vaccine, Buy Pfizer Stock for Its Impressive Cash Flow

 

A juicy 4.20% dividend makes PFE stock attractive buy for income-seekers

 

 If this month’s earth-shattering vaccine news from Pfizer (NYSE:PFE) has you thinking about buying the stock because it’s destined for monster gains – think again. PFE stock is not a growth play.

 

It’s a cash-flow vehicle.

 

But don’t take my word for it. Let the market be your guide. The tribe immediately rejected Pfizer’s bid to run wild after the news hit.

 

The message was clear. Stick to your lane, little stock. You’re a high dividend-paying, stable security with a history of enriching shareholders through those delicious quarterly checks. Perhaps someday your price chart will evolve into a rip-roaring uptrend, but not today.

 

By itself, this doesn’t mean PFE is not a great buy. It’s a wonderful candidate for income seekers. But, as I said, if you’ve come in search of rapid price appreciation, I fear you’ll be disappointed.

 

 

A Closer Look at PFE Stock

 

The S&P 500 sports a dividend yield of 1.48% and should be considered our baseline. Companies that offer payouts north of 1.48% are officially interesting as income-generating candidates.

 

Continue reading …